Please assess the completion status of the following clinical trial:

Trial Title: Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~1. Metastatic Her-2- breast cancer~2. Up to 2 prior lines of cytotoxic or targeted anti-cancer therapy for metastatic disease~3. Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1~4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1~Exclusion Criteria~1. Less than 6 months since prior neoadjuvant/adjuvant chemotherapy~2. Known central nervous system (CNS) disease, except for those participants with treated brain metastasis who are stable for at least 1 month, having no evidence of progression or hemorrhage after treatment and no ongoing requirement for corticosteroids, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period~3. Previous history or current evidence of deep vein thrombosis (DVT), hereditary thrombophilic syndromes, pulmonary embolism (PE), cerebral vascular accident (CVA), transient ischemic attack (TIA), atrial fibrillation (AF), or active carotid artery disease requiring treatment~4. Treatment with chemotherapy, hormonal, or biological therapy within the previous 3 weeks, radiation or small molecule targeted therapy within the previous 2 weeks preceding informed consent~5. Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eribulin mesylate plus PEGPH20 (Phase 1b) (Type: EXPERIMENTAL): Recommended Phase 2 dose (RP2D) will be determined from the below dose levels:~* Dose level 1: PEGPH20 (3.0 microgram per kilogram (mcg/kg)) followed by eribulin mesylate (1.4 milligrams per square meter (mg/m\^2)) or~* Dose level 0: PEGPH20 (1.6 mcg/kg) followed by eribulin mesylate (1.4 mg/m\^2) or~* Dose level -1: PEGPH20 (1.6 mcg/kg) followed by eribulin mesylate (1.1 mg/m\^2)~Dose level 1 can be selected as the RP2D if no more than 1 out of 6 participants has a DLT; DLT was only observed from the first treatment cycle; otherwise, Dose level 0 will be assessed in a second cohort of 6 subjects and will be selected as the RP2D if no more than 1 subject has a DLT. Otherwise, Dose level - 1 will be assessed in a third cohort of 6 subjects. Upon determination of the RP2D, study Phase 1b Expansion Part will proceed to confirm the RP2D, and thereafter Phase 2 part will proceed.
- Eribulin mesylate plus PEGPH20 (Phase 2) (Type: EXPERIMENTAL): Participants will receive eribulin mesylate and PEGPH20 at the established RP2D level achieved in the Phase 1b.
- Eribulin mesylate (Phase 2) (Type: EXPERIMENTAL): Participants will receive eribulin mesylate at 1.4 mg/m\^2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues